Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore

OCB appoints James Otter as new CEO

Oxford, UK, 15th July 2019:    Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth

Read More

Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity

  Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to

Read More

PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership

Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP).

Read More

Dr Kevin Xu, Chief Software Engineer, speaks at Chongqing and Henan Universities, China.

30/May/19 Last Friday (May 24th) Dr Xu, our Chief Software Engineer, gave an academic report on “Diagnosis, Prognosis and Predicting Biomarkers of

Read More

Rebecca survived the toxic effects of 5-FU against the odds. This is her story, in her words.

We are grateful to Rebecca for writing this and for her participation in the continuous improvement in our ToxNav® panel.

Read More

OCB and Meridian IT video explains ColoProg advances

The following is a video that shows how OCB and Meridian IT worked together to extend the development of our

Read More

OCB’s ColoPredict provides an accurate colorectal cancer screening that patients can trust

In a time when genetic tests are as commercially available as Christmas presents, it is more important than ever to

Read More

Publication of Review of Technologies Related to Diagnosis and Treatment of Stage II Colororectal Cancers by Key OCB Staff

  14th March 2019. OCB is proud to announce that an article on challenges and solutions in patient treatment strategies

Read More